AI Technology Group to change name to Biotechnology

AI Technology Group Inc. reported that its board of directors and stockholders holding a majority of the voting power have approved a corporate name change to Biotechnology, Inc. by joint written consent dated January 22, 2026.

Rhea-AI Filing Summary

AI Technology Group Inc. reported that its board of directors and stockholders holding a majority of the voting power have approved a corporate name change to Biotechnology, Inc. by joint written consent dated January 22, 2026.

Before this name change takes effect, a Company–Related Action will be submitted to FINRA for review. The filing does not describe any changes to the company’s business operations or financial condition in connection with this action.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What corporate change did AI Technology Group Inc. (AIPG) approve?

AI Technology Group Inc. approved a corporate name change to Biotechnology, Inc.. The change was authorized by the board of directors and stockholders holding a majority of the voting power through a joint written consent dated January 22, 2026.

Has the AI Technology Group Inc. (AIPG) name change to Biotechnology, Inc. taken effect?

The name change has been approved but is not yet effective. A Company–Related Action must first be submitted to FINRA for review. Implementation will occur only after that regulatory review process is completed and any required actions are taken.

Who approved the AI Technology Group Inc. (AIPG) name change?

The name change to Biotechnology, Inc. was approved by the company’s board of directors and stockholders representing a majority of the voting power. Their approvals were documented in a joint written consent dated January 22, 2026, authorizing the corporate action.

Does the AI Technology Group Inc. (AIPG) filing mention changes to operations or finances?

The filing focuses on the approved corporate name change to Biotechnology, Inc.. It does not describe any related changes to business operations, strategy, or financial condition, indicating the disclosure is limited to this governance and identity update.

What regulatory step is required for AIPG’s name change to Biotechnology, Inc.?

Before the name change becomes effective, a Company–Related Action must be submitted to FINRA for review. This step ensures the market and regulatory records properly reflect the new corporate name once implemented.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 09:56 AM Learn about SEC filing dates

0001289047false00012890472026-01-292026-01-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 29, 2026

 AI Technology Group Inc.

(Exact name of registrant as specified in its charter)

Nevada		000-1289047		20-1044677
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

50 W. Liberty St., Suite 880, Reno, NV		89501
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 800.394.7440

 _____________________________________________________

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Section 8-Other Events

Item 8.01 Other Events

Pursuant to a joint written consent dated January 22, 2026, of the Registrant's Board of Directors and stockholders constituting a majority of the voting power adopted certain resolutions to, among other matters, change the name of the Registrant to AVM Biotechnology, Inc. (the “Name Change”). Prior to implementing the Name Change, a Company –Related Action will be submitted to FINRA for review.

Section 9-Financial statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No		Description
101		Cover Page Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AI Technology Group Inc.
DATE: January 29, 2026	By:	/s/ Marcus Johnson
		Marcus Johnson, President

3